SciELO - Scientific Electronic Library Online

vol.117 issue2Epidemiological features and risk factors for mortality in Pseudomonas aeruginosa bacteremia in childrenCystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Archivos argentinos de pediatría

Print version ISSN 0325-0075On-line version ISSN 1668-3501


GIUBERGIA, Verónica et al. Clinical impact of omalizumab treatment in children with severe asthma: Report of a local experience. Arch. argent. pediatr. [online]. 2019, vol.117, n.2, pp.e115-e120. ISSN 0325-0075.

Omalizumab, an anti-IgE monoclonal antibody, is indicated for the treatment of severe asthma. A longitudinal (pre-/post-intervention), observational, analytical study was conducted to assess the clinical and functional course of patients with uncontrolled severe asthma, 16 weeks before and after treatment. Asthma was controlled in 17 cases (p = 0.00001). Exacerbations were reduced by 48.5 % (p = 0.009) and severe crises, by 100 % (p = 0.001). Before omalizumab treatment, 16 patients (94 %) had exacerbations, whereas 10 (59 %) had them after treatment (p = 0.005). None of the patients was hospitalized (p = 0.007). The dose of inhaled corticosteroids was reduced by 20 % (0.002); the number of patients using continuous oral corticosteroids (p = 0.01), salbutamol (p = 0.001), and oral corticosteroids (p=0.003) also decreased. Pulmonary function was not affected. Two patients had mild adverse reactions. Omalizumab achieved an adequate asthma control in patients with severe asthma.

Keywords : Asthma; Child; Omalizumab.

        · abstract in Spanish     · text in Spanish


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License